A Phase Ib/II Multicenter, Randomized, Open-label, Active-controlled, Single/Multiple-dose, Dose-finding, Clinical Study of GenSci134 in Children With Growth Hormone Deficiency
Latest Information Update: 10 Mar 2026
At a glance
- Drugs GenSci 134 (Primary) ; Somatropin
- Indications Somatotropin deficiency
- Focus Adverse reactions; Therapeutic Use
- Sponsors GeneScience Pharmaceuticals
Most Recent Events
- 10 Mar 2026 New trial record